An observational study in Rheumatoid Arthritis, sponsored by University Hospital, Montpellier. Suspended at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University Hospital, Montpellier · Observational
Evolution of treatment sequencing for JAK inhibitors
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.
Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2021, is one of 12 observational ones, and was the 15th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18–80 · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 87 across the 15 interventional studies, 182 across the 12 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Arthritis, Rheumatoid by University Hospital, Montpellier that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Personalized medicine in which each patient would receive the ideal personalized treatment and regimen, holds great promise to improve patient's care. However, previous studies failed to establish validated predictors of response to disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). JAK inhibitors is a new class of DMARDs with great efficacy that might be even superior to anti-TNF drugs. As there are chemicals, their production cost is much cheaper than biological therapies and they will probably be central in patient's care in the coming years. Three are currently available: upadacitinib (UPA) tofacitinib and baricitinib. Our study will focus on UPA. Clinical outcomes mainly depend on i) factors influencing drug metabolism \& concentrations and ii) adequacy between drug target and the inflammation pathways involved in the patient's disease. Humans carry in their gut trillions of germs, which are now known to be key players in health and disease. Those germs possess many enzymes and strongly modulate human enzymes expression. Gut-microbiota can, indeed, directly metabolize oral drugs and control the expression of the cytochrome P450 3A4 (CYP3A4), the main enzyme metabolizing TOFA. We showed, in a preliminary mouse experiment, that modifying gut-microbiota composition changes JAKi effects on signaling pathways. We thus believe that models including gut-microbiota composition together with markers of immune activation will predict clinical outcomes in RA patients treated with UPA.
Main and secondary objectives: To build predictive models for clinical outcomes (efficacy and safety) of RA patients treated with UPA based on microbiota analysis and markers f immune activation.
Methodolgy:
This multicentric longitudinal prospective study will include 60 patients with RA and inadequate response to methotrexate. The clinical outcomes studied will be EULAR non-response at 3 months as defined by the European league against rheumatism EULAR (primary outcome), achievement of low-disease activity at 6 months or incident adverse events (secondary outcomes). Gut microbiota will be assessed at baseline and M3 from thawed fecal samples. DNA will be purified using QIAamp DNA stool mini kit (Qiagen) and qualify using Qubit and TapeStation 4200 (Agilent). Library will be prepared by amplification of V1-V2 and V3-V4 regions from the bacterial 16S rRNA genes and will be qualified by q-PCR and amplicons will be sequenced by MiSeq (Illumina). Initial bioinformatic analysis and taxonomies will be carried out using the QIIME2 software. Immune activation will be assessed through JAK-STAT pathway activation by JAK STAT signaling pathway RT² profiler PCR Array (Qiagen) which profiles expression of 84 genes related to Jak and Stat-mediated signaling. UPA concentrations will be assessed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at baseline and 3 months. Statistical classifiers (Neural network algorithm, Linear and Quadratic Discriminant Analysis, Support Vector Machine, Random forests, Shrinkage Methods, or Nearest Neighbors) incorporating microbiome, JAK STAT signaling pathway gene expression and clinical data, will be used to determine profiles associated with UPA clinical response and safety. Patients who will prematurely stop UPA (before 3 months) for adverse events or loss of follow-up will be considered as non-responders.
Gut microbiota is becoming an important predictor of response and tolerance with anti-cancer drugs. However, its potential of prediction in other fields has poorly been explored.
Drug metabolism and concentrations of tofacitinib depend on body mass index, liver function and cytochrome P450 activity (especially CYP3A4). Humans carry in their gut trillions of germs, which are now known to be key players in health and disease. Those germs can strongly impact drug metabolism and concentrations based on 3 mechanisms. First, gut bacteria possess a huge pool of enzymes which catalyzes drug metabolism reactions. Second, gut microbiota regulates bile acid metabolism which play critical role in drug metabolism. Third, gut microbiota modulates the expression of cytochrome P450, especially CYP3A4, the main enzyme catabolizing Tofacitinib (TOFA).
In addition to drug metabolism, gut microbiota is a key driver of immune activation. Clinical response to CTLA-4 or anti-PD-1 strongly depends on gut microbiota in different cancers. The experiments performed to decipher the mechanisms involved suggested that microbiota composition affects immune responses, which will facilitate or not anti-tumoral efficacy of checkpoints inhibitors.
RA is a heterogeneous disease with predominant inflammation pathways varying dependent on patients. Some RA seem to be more dependent on IL-6 whereas others rely more on TNF-alpha, B or T cells. Gut microbiota was shown to affect all those different targets. Assessing baseline levels of JAK STAT signaling pathway gene expression will help us to link immune activation, gut microbiota and clinical response to UPA.
We hypothesize that gut-microbiota composition impacts JAKi metabolism, immune activation, and thus clinical response and has a great potential to predict clinical outcomes in patients with RA treated with UPA.
Study objectives :
Main objective
To construct a model based on gut-microbiota composition, immune activation markers (JAK-STAT signalling pathway) and clinical data to predict UPA non-response at 3 months in RA patients with inadequate response to methotrexate.
Secondary objectives
To compare responders and non-responders and patients with or without adverse effects on UPA in terms of:
To correlate changes in disease activity score based on 28 joint evaluation (DAS28, see annex for calculation) between month-3 and baseline with:
Patients with RA fulfilling American College of Rheumatology (ACR)/ European league against rheumatism (EULAR) 2010 criteria with inadequate response to MTX for who a treatment with UPA will be prescribed in standard care to control disease activity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
EULAR response
Response will be defined following European league against rheumatism EULAR definition that is a decrease \>0.6 points of Disease-Activity-Score 28-joints (DAS28-CRP) and a DAS28-CRP≤5.1 at 3 months . Patients who will prematurely stop UPA (before 3 months) for adverse events, RA flair or loss of follow-up will be considered as non-responders.
Time frame: 3 months
EULAR good response
EULAR good-response at 3 and 6 months: DAS28-CRP≤3.2 and deltaDAS28 (M0-M3)\>1.2
Time frame: 3 and 6 months
Achievement of low-disease activity:
DAS28-CRP at 6 months \<3.2 and/or DAS28-ESR at 6 months \<3.2
Time frame: 6 months
Adverse events
Incidence, relatedness, and severity of treatment-emergent SUSARs, SAEs, ARs and AEs will be evaluated continuously. Patients with adverse events occurring between study visits will be asked to contact the study center for AE reporting.
Time frame: during the 6 month follow-up
Baseline gut-microbiota
microbiota will be described in terms of alpha and beta diversity, phylum, genus, OTU.
Time frame: baseline, 3 and 6 months
UPA concentrations
Time frame: 0, 3 and 6 months
Baseline JAK-STAT signalling pathway gene expression profile
gene expression profile will include the level of expression of 84 genes
Time frame: baseline
Baseline clinical data
DAS28-CRP, body-mass index, age and gender
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Sep 2026, 68 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Apr 2024 → Sep 2026 and completion Oct 2024 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Evolution of treatment sequencing for JAK inhibitors
Evolution of treatment sequencing for JAK inhibitors
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →